Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor

A complement inhibitor, patient technology, applied in the direction of drugs or prescriptions, drug reference, pump control, etc., can solve the problem of high infection complications

Inactive Publication Date: 2014-12-10
ALEXION PHARMA INC
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the risk of infectious complications may be highest when blocking the rather upstream complement component C3

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
  • Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
  • Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0068] The present disclosure generally relates to methods for delivering drugs, particularly drugs that inhibit complement activation pathways, to a patient. As used herein, the term "drug" refers to any substance intended for use in the diagnosis, cure, alleviation, treatment or prevention of a disease or in affecting the structure or function of the body. In general, the methods of the present disclosure can be expected and advantageously used to educate and reinforce the actions and behaviors of patients who take the drug, as well as the prescribers who prescribe the drug and the pharmacies that dispense the drug. Education and reinforcement of such actions and behaviors are often required to ensure proper prescribing and dispensing of medications, and patient compliance with taking medications. In some cases, patient and prescriber education about drug discontinuation is also required. Discontinuation of a drug can result in adverse effects, and patients and prescribers ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This disclosure relates to methods of authorizing distribution of complement-inhibiting drugs to patients who have a complement-associated disorder in a manner to ensure that the patients are aware of the possible dangers of discontinuing treatment with the drugs. A database is prepared comprising patient information including experiencing adverse clinical events after discontinuing the drug treatment. The information in the database is collected and may be reported. The patients are given a warning as to adverse events that may occur if treatment with the complement inhibiting drugs is discontinued.

Description

technical field Background technique [0001] Complement is an essential component of the immune system and has important relevance for the destruction of invading microorganisms and for maintaining tissue homeostasis including protection against autoimmune disease. However, excessive or uncontrolled complement activation contributes significantly to unwanted tissue damage. Complement activation presents a considerable risk of harming the host by directly and indirectly mediating inflammatory tissue destruction. Clinical and experimental evidence emphasizes the prominent role of complement in the pathogenesis of numerous inflammatory diseases. [0002] In recent years, significant progress has been made in inhibiting complement activation as a potential treatment for complement-associated diseases. Some degree of inhibition of complement activation may be sufficient to reduce its deleterious effects, yet preserve defense mechanisms against invading pathogens. Redundancy of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G06Q50/22G16H20/10G16H70/40
CPCG06Q50/22G01N33/50F04C2270/041G16H20/10G16H70/40
Inventor L·贝尔
Owner ALEXION PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com